Faculty & Researchers

Dr. Lin received the B.S. degree from Rensselaer Polytechnic Institute and the Ph.D. degree from Duke University, all in biomedical engineering. He is currently the Director for Clinical Research in North America for Visage Imaging and is stationed at Yale-New Haven Hospital where he oversees, coordinates, drives and directs research collaborations with high profile academic hospitals in North America to develop new solutions for diagnostic image analysis and guidance that improve clinical and operational outcomes while reducing cost of care. This includes Artificial Intelligence (AI) and Machine Learning (ML) applications in the Radiology enterprise diagnostic imaging solutions space. Dr. Lin identifies opportunities for academic-industry research partnerships, and acts as the liaison between Visage Imaging researchers and clinical collaborators to translate ideas to prototype for clinical validation, with the goal of technology transfer to product. A highlight is Ming coordinated the clinical data curation and ground-truth annotation for building a fully automatic breast density AI classifier that provides an ACR BI-RADS Atlas 5th Edition breast density category to aid radiologists in the assessment of breast tissue composition from full field digital mammography and digital breast tomosynthesis systems and drove the clinical validation with Yale radiologists and Visage developers that led to transfer to product and regulatory approvals in 21 months following IRB approval and has been in full clinical production use at Yale since April 2021. Moreover, Dr. Lin directed the study with Yale radiologists to assess the AI algorithm’s post-clinical deployment performance, and we found there was 99.35% agreement in classifying the breast density between the AI and the radiologist. This was the first FDA-cleared AI algorithm that reported having >1000 patients for validating the AI from two different clinical sites: Yale and New York University (NYU), and it was the first for a major PACS vendor to offer a self-developed, FDA-cleared AI algorithm natively into their PACS: Visage Breast Density, K201411, 510(k) clearance, January 2021, Health Canada Licensed, October 2020, Australian TGA approval, July 2020, CE Mark Cleared, May 2020. Another effort Dr. Lin is working on is multi-institution AI research to develop robust deep learning methods for generating patient-specific virtual-high-count PET images from standard PET images, thereby saving imaging time, reducing radiation dose, and increasing scanner longevity. This work is being conducted in an NIH R01 academic-industry partnership grant where Dr. Lin is the Visage Imaging, Inc. Principal Investigator (PI), and the other partners are Yale New Haven, Massachusetts General Brigham, and University of California Davis hospitals. Dr. Lin also is directly involved in research to develop better ways to treat patients with liver cancer using transcatheter arterial chemoembolization (TACE), and in this context, he is also the chief engineer and operations manager of the Yale Interventional Oncology Research Lab. Dr. Lin is Principal Investigator (PI) on two NIH R01 grants and the Industry PI on its renewal NIH R01 grant (three grants in total) to improve the diagnosis, treatment, and response assessment after transcatheter arterial chemoembolization for patients with liver cancer. Dr. Lin is the inventor of 3D quantification TACE therapy response tool (qEASL) and in collaboration with clinical partners, validated, and showed clinical relevance (ability to predict patient survival) that led to transfer to commercial product (FDA 510(k) cleared December 2016 - Multi-Modality Tumor Tracking (MMTT) application). Prior to Visage Imaging, Dr. Lin was the Philips research site manager and senior researcher stationed onsite at Yale where he managed the research portfolio and partnership Philips has with Yale.

Dr. Chapiro is an Associate Professor in Radiology, Digestive Diseases (Hepatology) and in Biomedical Engineering, Principal Investigator of the Yale Interventional Oncology Research Lab and Director of the Center for Minimally Invasive Therapies. After graduating from the University of Leipzig and upon completion of his research thesis at the Justus-Liebig University in Giessen with summa cum laude, he served as a postdoctoral research fellow in interventional oncology at The Johns Hopkins Hospital and then as radiology resident at the Department of Radiology, Charité University Hospital in Berlin. He joined the Department of Radiology and Biomedical Imaging in 2016 as a research scientist and interventional radiology resident from Berlin, Germany. Dr. Chapiro’s research focuses on developing new quantitative imaging biomarkers for the diagnosis, characterization, and therapeutic management of liver cancer. His translational research portfolio includes the development of novel embolic agents as well as the application of artificial intelligence solutions for the management of liver cancer. His basic research interest mainly focuses on developing new tools to characterize the tumor microenvironment and the immune system in the setting of loco-regional, image-guided therapies of liver cancer. Creating innovative and clinically applicable imaging solutions for liver cancer with advanced molecular imaging, image post-processing and machine learning approaches and translating them to clinical practice has been his central mission for the past decade. He authored and co-authored >150 original research articles, reviews and book chapters and gave more than 100 talks and invited lectures within the last seven years. His research has also resulted in several patents, 510(k)-approved medical products and significant grant support from federal, foundational and industry sources. He is an active research mentor to more than 50 undergraduate, medical and graduate students as well as peers both at Yale and other national and international institutions. Being an active contributor, journal-, abstract- and grant reviewer in several professional societies (RSNA, SIR and SIO), he is also committed to education and the mission of disseminating research data and scientific knowledge. Dr. Chapiro consults the Editorial Board of the Journal of Hepatology and Radiology (RSNA), is a member of the American College of Radiology Liver Imaging Reporting and Data System (LI-RADS) Steering Committee, he additionally chairs the Grant Committee of the Society of Interventional Oncology and is the Chair of the Annual Meeting Program Planning Committee for the Subspecialty of Interventional Radiology at the Annual Radiological Society of North America meeting 2021-2023. He is the co-initiator of the "Rising Star" Student Exchange Program in collaboration with the Charité University Hospital in Berlin and directs the Center for Minimally Invasive Therapies. Dr. Chapiro is the Associate Director of the Clinical and Translational Core of the Yale Liver Center.

Eliot Funai graduated from the University of Maryland, Baltimore County, and previously worked at Johns Hopkins University before coming to Yale. His work as a clinical research coordinator is to develop and oversee the management and execution of clinical trials, primarily concerning locoregional therapies for treating liver cancers. His experience is with investigator initiated studies, industry and NIH-funded trials, and cooperative group studies.

Fabian M. Laage Gaupp graduated from medical school at Ludwig Maximilians University Munich, completed a surgical intern year at Cornell Presbyterian Hospital in New York, followed by residency training in Diagnostic and Interventional Radiology at Yale New Haven Hospital, where he served as Chief Resident of Interventional Radiology in 2020-2021.  Dr. Laage Gaupp specializes in Men's and Women's Health, offering minimally invasive treatments for benign prostatic hyperplasia (BPH) and uterine fibroids. Image guided prostate artery embolization and uterine fibroid embolization provide effective treatment of these very common conditions on outpatient basis without need for major surgery, allowing patients to go home the same day.  He is a co-founder of Road2IR, an international consortium lead by Yale, Muhimbili University of Health and Allied Sciences (MUHAS) in Tanzania, Emory, and other institutions in North America and Europe which has established the first accredited IR training program in sub-Saharan Africa. The project was awarded with an RSNA R&E Foundation Derek Harwood-Nash International Education Scholar Grant in 2020 and MUHAS was selected as the world's second RSNA Global Learning Center (GLC). The program now serves as a blueprint for partner programs in Rwanda and Uganda, aiming to bring minimally invasive IR procedures to more patients in East Africa and beyond.

Postgraduate research fellow (MD thesis) - Yale Interventional Oncology Lab Fourth-year medical student at the Charite Universitätsmedizin Berlin, Germany.

Hometown: Tabriz, Iran Medical School: Tabriz University of Medical Sciences Professional Interests: Diagnostic and Interventional Radiology; Clinical Outcomes Research; History of Medicine Personal Interests: Swimming, painting pottery, reading medieval medical books, and spending time with my wife and friends

Third year medical student at Charite, School of Medicine Berlin. Research Fellow at the Department of Radiology and Biomedical Imaging.

Jessica is currently pursuing her PhD in Biomedical Engineering at Yale. She received her B.Sc in Biomedical Sciences from the Universidade Estadual de Santa Cruz (UESC), Brazil, with further research experience from McGill University, Canada, and Harvard School of Public Health, USA through the Science Without Borders Scholarship Program. Upon graduating from UESC, she received her fully funded master’s degree in Biomedical Sciences with a focus on cancer development and immune responses from Radboud Universiteit, Netherlands. She concluded her program at the Department of Immunobiology at Yale University. She worked as a Postgraduate Research Associate at the Department of Radiology and Biomedical Imaging, where she optimized animal models of liver cancer for molecular characterization of the tumor microenvironment to loco-regional therapies from an imaging perspective.